Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy
处于癌症免疫治疗前沿的新兴细胞疗法
基本信息
- 批准号:10540496
- 负责人:
- 金额:$ 1.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-29 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AchyroclineAddressAffectAlberta provinceAntibodiesAreaBenignBiodistributionBiological ProductsBiologyCanadaCell Culture TechniquesCell TherapyCellsCellular biologyCellular immunotherapyChemistryCollaborationsDevelopmentDrug KineticsEducational workshopEffectivenessEngraftmentEventExtravasationFunctional disorderFutureGene TransferGeneticGenome engineeringHematologic NeoplasmsImmuneImmunosuppressionIndividualIndustrializationIntuitionKnowledgeLearningMalignant - descriptorMalignant NeoplasmsMetabolicMethodologyModelingNormal tissue morphologyOutcomeResearchResearch PersonnelScientistSolid NeoplasmSpeedTechnologyTherapeuticTherapeutic IndexTimeTissuesToxic effectTranslationsTumor BiologyWorkcancer cellcancer immunotherapycancer therapycareerclinical implementationclinical practicedifferential expressionfitnessholistic approachimprovedin vivoinsightinterestmultidisciplinaryneoplasticnew technologynext generationnovelnovel strategiespostersprogramsresiliencesmall moleculesuccesssymposiumsynthetic biologytraffickingtranslational scientist
项目摘要
ABSTRACT
Support is requested for a Keystone Symposia conference entitled Emerging Cellular Therapies at the
Forefront of Cancer Immunotherapy, organized by Drs. Francesco Marincola, Lisa Butterfield, David Stroncek
and Marcela Maus. The conference will be held in Banff, Alberta, Canada from January 29-February 2, 2023.
Cellular immunotherapy for the treatment of hematological malignancies and solid tumors is rapidly
progressing. Progress depends upon the development of better products that match the challenges limiting
effectiveness such as survival and engraftment, trafficking to cancer tissues, engagement with cancer cells,
and resilience to immune-suppressive factors while at the same time de-risking toxicity. This can be only
achieved following a holistic approach to achieve an optimal therapeutic index. Such estimation goes beyond
the selection of antigenic targets based of differential expression between benign and neoplastic tissues as is
intuitively done for small molecules, antibodies and other biologics where the engagement of the product with
its target is dependent on stable chemistry and predicable pharmacokinetics. Cell therapies instead are
affected by active rather than passive biodistribution, and context dependent potency. Thus, a broader range
of factors need to be considered like product-dependent variability (fitness, unpredictable pharmacokinetics
due non-specific trapping, sequestration and extravasation into normal tissues, and variable rates of in vivo
expansion). Individual cancer immune biology may affect differential trafficking to benign compared to
malignant tissues under different conditions of chemo-attraction, hampered engagement with cancer cells due
to physical or functional barriers, immune suppression, and cellular dysfunction due to unfavorable metabolic
conditions. This conference gathers expertise from all areas, to propose an integrated path forward to
successful implementation of novel cellular therapeutics, particularly for solid tumors.
摘要
请求支持在2010年12月15日至16日在纽约举行的题为“新兴细胞疗法”的Keystone专题讨论会。
癌症免疫疗法前沿,由Francesco Marincola、丽莎巴特菲尔德、大卫斯特龙切克博士组织
还有马塞拉·莫斯会议将于2023年1月29日至2月2日在加拿大阿尔伯塔省班夫市举行。
用于治疗恶性血液病和实体瘤的细胞免疫疗法正在迅速发展。
进步进步取决于开发更好的产品,以满足限制
有效性,如存活和植入,运输到癌组织,与癌细胞的接合,
和对免疫抑制因素的适应力,同时降低毒性风险。这只能是
采用整体方法实现最佳治疗指数。这种估计超出了
基于良性和肿瘤组织之间的差异表达的抗原靶标的选择,
直观地为小分子,抗体和其他生物制剂,其中产品与
其靶点依赖于稳定的化学性质和可预测的药代动力学。细胞疗法是
受主动而非被动生物分布的影响,以及环境依赖性效力。因此,
需要考虑多种因素,如产品依赖性变异性(适应性、不可预测的药代动力学
由于非特异性捕获、隔离和溢出到正常组织中,以及体内的变化率
扩展)。个体癌症免疫生物学可能会影响与良性肿瘤相比的差异性运输。
恶性组织在不同条件下的化学吸引力,阻碍了与癌细胞的接触,
身体或功能障碍,免疫抑制和细胞功能障碍,由于不利的代谢
条件本次会议汇集了所有领域的专业知识,提出了一条综合的前进道路,
成功实施新的细胞疗法,特别是用于实体瘤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TERRY L. SHEPPARD其他文献
TERRY L. SHEPPARD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TERRY L. SHEPPARD', 18)}}的其他基金
Pulmonary Hypertension: State of the Art and Therapeutic Opportunities
肺动脉高压:最新技术和治疗机会
- 批准号:
10682118 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Infections in Pregnancy: PathogenicMechanisms, Experimental Advances and Clinical Strategies
妊娠期感染:致病机制、实验进展和临床策略
- 批准号:
10540260 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Mechanisms of Microbiota-Immune Interactions-Towards the Next Decade
微生物群-免疫相互作用的机制-迈向下一个十年
- 批准号:
10753451 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Transposable Elements at the Crossroads of Evolution, Health and Disease
处于进化、健康和疾病十字路口的转座元件
- 批准号:
10750852 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Long COVID and Post Acute Sequalae of SARS CoV 2 (PASC): Pathogenesis and Treatment
长期新冠肺炎和 SARS CoV 2 (PASC) 急性后遗症:发病机制和治疗
- 批准号:
10749522 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers
传染病、自身免疫和 B 细胞癌症背景下的 B 细胞生物学
- 批准号:
10683443 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Inflammation in the Lung: Friend or Foe in Viral Infections?
肺部炎症:病毒感染的朋友还是敌人?
- 批准号:
10681956 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 1.1万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 1.1万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 1.1万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 1.1万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 1.1万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 1.1万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 1.1万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 1.1万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 1.1万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 1.1万 - 项目类别:
Research Grant